Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.
The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.
It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.
According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.
Thane Sessions Court Rejects Bail Plea Of Businessman Accused In ₹37 Crore GST Fake Invoice Fraud Case
VIDEO: Devotees Crushed After Ganesh Idol Falls From Crane During Immersion In Telangana
Who Was Ayush Alias Govind Komkar? 20-Year-Old Shot Dead In Pune’s Nana Peth On Ganpati Visarjan Eve
Navi Mumbai Tragedy: Couple Killed After Being Run Over By Speeding Dumper Near Vashi Toll Naka; Case Registered
The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.
